26.03.2008 11:30:00
|
Applied Biosystems Advances Cell-Based Gene Expression Research
Applied Biosystems (NYSE:ABI), an Applera Corporation business, today
announced a new family of real-time PCR reagent kits that enable
researchers to more rapidly perform cell-based gene expression research.
The TaqMan® Cells-to-CT™
Kit solutions are chemical reagents that are designed to reduce the
amount of time that is typically necessary to prepare and analyze RNA
from cultured cells using real-time PCR in applications such as
siRNA-mediated gene silencing and microRNA analysis.
This family of kits enables expression analysis to be performed directly
from cultured mammalian cells derived from a variety of tissue sources,
including epithelial cells and stem cells. Integrating gold-standard
TaqMan chemistry, these kits are part of a complete workflow that has
been designed with all the necessary reagents for performing expression
analysis and are validated for use with Applied Biosystems’
TaqMan Assays and Arrays. These new, streamlined workflows eliminate the
time-consuming step of RNA purification and reduce the traditionally
labor intensive process of preparing samples to 10 minutes or less,
compared to 30-60 minutes when using traditional methods.
These reagents, which are manufactured and validated by Applied
Biosystems, are optimized for use with the company’s
industry-leading real-time PCR instrument systems. The TaqMan
Cells-to-CT kits expand Applied Biosystems’
portfolio of real-time PCR workflows. They include:
TaqMan® Gene Expression Cells-to-CT™
Kit for gene expression analysis from mRNA.
TaqMan® PreAmp Cells-to-CT™
Kit for preamplification of selected targets when using precious
or limited samples.
TaqMan® MicroRNA Cells-to-CT™
Kit for microRNA expression analysis.
TaqMan® Fast Cells-to-CT™
Kit (expected to be released May 2008) for gene expression
analysis with Fast Real-Time PCR.
"The development of these new reagents
demonstrates Applied Biosystems’ continued
strategic focus on bringing high-quality, application-specific solutions
for real-time PCR to market,” said Peter
Dansky, president of Applied Biosystems’
functional analysis division. "Our customers
are continuing to derive new applications for real-time PCR, and we
intend to continue to play a leading role in providing them with
differentiated solutions that are tailored to their specific research
workflows.”
Real-time PCR is a laboratory method that is widely used in academic and
industry laboratories to simultaneously detect and determine the amount
of nucleic acids present in samples. Research data generated using these
reagents can help researchers to precisely assess how changes in the
amounts of RNA in these cells may contribute to the development of
disease, as well as how they relate to biological processes.
For instance, Reproductive Medicine Associates of New Jersey, one of the
world's largest and most experienced centers for infertility treatment,
utilizes real-time PCR in its research, which focuses on developing new
diagnostics and therapeutics for in-vitro fertilization. Scientists at
the center have developed an innovative procedure for screening all 46
human chromosomes to identify abnormalities in embryos, and have begun
to determine when stem cells differentiate during pre-implantation
embryonic development. They are using the TaqMan Gene Expression
Cells-to-CT Kit for several projects including the characterization of
single cells in three-day old embryos. This particular kit allows them
to rapidly process RNA and directly analyze it on TaqMan Arrays without
purification. This is a new time saving workflow that is uniquely
enabled by the kit. It also eliminates the loss of RNA, which is
particularly important for downstream gene expression analysis of single
cells.
"The use of real-time PCR is critical to our ability to perform
expression analysis on stem cells," said Dr. Nathan Treff, Ph.D.,
director of molecular biology at Reproductive Medicine Associates of New
Jersey. "Using the TaqMan Gene Expression Cells-to-CT Kit and TaqMan
Arrays, we have been able to bring efficiencies to our real-time PCR
workflow, while increasing the throughput of our lab 10-fold."
The complete family of TaqMan Cells-to-CT Kit solutions have been
extensively tested and validated to work with Applied Biosystems’
line of TaqMan®
MicroRNA Assays and TaqMan® Gene Expression Assays and TaqMan Arrays. Applied Biosystems is a
global leader in the development and commercialization of
instrument-based systems, consumables, software, and services for the
life-science market. The company’s
comprehensive line of real-time PCR chemistries and instrument systems
includes the Applied Biosystems 7900HT Fast Real-Time PCR System, 7500
Real-Time PCR System, 7500 Fast Real-Time PCR System, 7300 Real-time PCR
System, StepOne™ Real-Time PCR System, and
StepOnePlus™ Real-Time PCR System.
For more information about the new TaqMan Cells-to-CT kits and Applied
Biosystems complete line of real-time PCR please visit www.appliedbiosystems.com/c2ct.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. Applied Biosystems
serves the life science industry and research community by developing
and marketing instrument-based systems, consumables, software, and
services. Customers use these tools to analyze nucleic acids (DNA and
RNA), small molecules, and proteins to make scientific discoveries and
develop new pharmaceuticals. Applied Biosystems’
products also serve the needs of some markets outside of life science
research, which we refer to as "applied
markets,” such as the fields of: human
identity testing (forensic and paternity testing); biosecurity, which
refers to products needed in response to the threat of biological
terrorism and other malicious, accidental, and natural biological
dangers; and quality and safety testing, such as testing required for
food and pharmaceutical manufacturing. Applied Biosystems is
headquartered in Foster City, CA, and reported sales of approximately
$2.1 billion during fiscal 2007. The Celera Group is a diagnostics
business delivering personalized disease management through a
combination of products and services incorporating proprietary
discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services
to predict cardiovascular disease risk and optimize patient management.
Celera also commercializes a wide range of molecular diagnostic products
through its strategic alliance with Abbott and has licensed other
relevant diagnostic technologies developed to provide personalized
disease management in cancer and liver diseases. Information about
Applera Corporation, including reports and other information filed by
the company with the Securities and Exchange Commission, is available at http://www.applera.com,
or by telephoning 800.762.6923. Information about Applied Biosystems is
available at http://www.appliedbiosystems.com.
All information in this press release is as of the date of the release,
and Applera does not undertake any duty to update this information
unless required by law.
Applied Biosystems Forward Looking Statements
Certain statements in this press release are forward-looking. These may
be identified by the use of forward-looking words or phrases such as "should,” "expect,” and "planned,”
among others. These forward-looking statements are based on Applera
Corporation’s current expectations. The
Private Securities Litigation Reform Act of 1995 provides a "safe
harbor” for such forward-looking statements.
In order to comply with the terms of the safe harbor, Applera
Corporation notes that a variety of factors could cause actual results
and experience to differ materially from the anticipated results or
other expectations expressed in such forward-looking statements. These
factors include but are not limited to: (1) rapidly changing technology
and dependence on the development and customer acceptance of new
products; (2) sales dependent on customers’
capital spending policies; and (3) other factors that might be described
from time to time in Applera Corporation's filings with the Securities
and Exchange Commission. All information in this press release is as of
the date of the release, and Applera does not undertake any duty to
update this information, including any forward-looking statements,
unless required by law.
For research only. Not for use in diagnostic procedures.
Copyright© 2008. Applera Corporation. All
Rights Reserved.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Applera Corp. - Applied Biosystemsmehr Nachrichten
Keine Nachrichten verfügbar. |